Details for Patent: 7,727,982

Title:	Benzamides and related inhibitors of factor Xa
Abstract:	Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compound and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
Inventor(s):	Zhu; Bing-Yan (Palo Alto, CA), Zhang; Penglie (Foster City, CA), Wang; Lingyan (East Brunswick, NJ), Huang; Wenrong (Cupertino, CA), Goldman; Erick A. (Concord, CA), Li; Wenhao (Union City, CA), Zuckett; Jingmei (Bellevue, WA), Song; Yonghong (Foster City, CA), Scarborough; Robert M. (Half Moon Bay, CA)
Assignee:	Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Filing Date:	Jul 17, 2006
Application Number:	11/488,455
Claims:	1. A compound of the formula: A-D-E-G-J-K wherein: A is a 5-10 membered saturated monocyclic heterocyclic ring system containing 1-4 heteroatoms selected from N, O and S, wherein 1-2 ring atoms of the heterocyclic ring system are substituted with 1-2 R.sup.1 groups; R.sup.1 is C .sub.1-6-alkyl; D is phenyl or pyridine where the phenyl is attached to rest of the compound in the 1,4-position and the pyridine is attached to the rest of the compound in the 2,5-position; E is --C(.dbd.O)--NH-- or --NH--C(.dbd.O)--; G is a phenylene group wherein the ring carbon atoms of the phenylene group are substituted with 0-2 R.sup.1d groups and the phenylene group is attached to the rest of the compound at the 1,2-position; R.sup.1d is --(CH.sub.2).sub.0-6 OR.sup.2d; R.sup.2d is H or C.sub.1-6-alkyl; J is --C(.dbd.O)--NH-- or --NH--C(.dbd.O)--; K is a phenyl substituted with 0-3 R.sup.1e groups; R.sup.1e is a member independently selected from the group consisting of: halo and --(CH.sub.2).sub.0-2--O--R.sup.2e; R.sup.2e is independently a member selected from the group consisting of: H and --C.sub.1-4-alkyl; or a pharmaceutically acceptable isomer, salt, hydrate, or prodrug derivative thereof. 2. The compound of claim 1, wherein E is --N(H)--C(O)--. 3. The compound of claim 1, wherein J is --N(H)--C(.dbd.O)--. 4. The compound of claim 1, wherein R.sup.1 is methyl. 5. The compound of claim 1, wherein A-D- is ##STR00641## 6. The compound of claim 1, wherein E is --C(.dbd.O)--NH--. 7. The compound of claim 1, wherein R.sup.1d is --OR.sup.2d. 8. The compound of claim 7, wherein R.sup.1d is --OH. 9. The compound of claim 1, wherein J is --C(.dbd.O)--N(--R.sup.6)-- and R.sup.6 is hydrogen. 10. The compound of claim 1, wherein R.sup.1e is chloro. 11. The compound of claim 1, wherein R.sup.1e is --OCH.sub.3. 12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of claim 1.